Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eiger Biopharmaceuticals (DE:72C1)
FRANKFURT:72C1
RESEARCH TOOLSreports
Eiger Biopharmaceuticals (72C1) Stock Price & Analysis
1 Followers
72C1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€4.05 - €79.53
Previous Close€6.18
Volume0.00
Average Volume (3M)81.00
Market Cap
€9.68M
Enterprise Value€11.07M
Total Cash (Recent Filing)$39.42M
Total Debt (Recent Filing)$40.94M
Price to Earnings (P/E)N/A
Beta1.11
Next Earnings
Mar 14, 2024EPS Estimate
-€6.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding44,384,684
10 Day Avg. Volume250
30 Day Avg. Volume81
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-6.41
Price to Sales (P/S)3.26
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.77
Enterprise Value/Gross Profit0.82
Enterprise Value/Ebitda-0.17
Forecast
1Y Price Target
€27.33Price Target Upside342.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Eiger Biopharmaceuticals News
72C1 FAQ
What was Eiger Biopharmaceuticals’s price range in the past 12 months?
Eiger Biopharmaceuticals lowest stock price was €4.05 and its highest was €79.53 in the past 12 months.
What is Eiger Biopharmaceuticals’s market cap?
Currently, no data Available
When is Eiger Biopharmaceuticals’s upcoming earnings report date?
Eiger Biopharmaceuticals’s upcoming earnings report date is Mar 14, 2024 which is 53 days ago.
How were Eiger Biopharmaceuticals’s earnings last quarter?
Eiger Biopharmaceuticals released its earnings results on Nov 09, 2023. The company reported -€10.608 earnings per share for the quarter, missing the consensus estimate of -€8.518 by -€2.09.
Is Eiger Biopharmaceuticals overvalued?
According to Wall Street analysts Eiger Biopharmaceuticals’s price is currently Undervalued.
Does Eiger Biopharmaceuticals pay dividends?
Eiger Biopharmaceuticals does not currently pay dividends.
What is Eiger Biopharmaceuticals’s EPS estimate?
Eiger Biopharmaceuticals’s EPS estimate is -€6.34.
How many shares outstanding does Eiger Biopharmaceuticals have?
Currently, no data Available
What happened to Eiger Biopharmaceuticals’s price movement after its last earnings report?
Eiger Biopharmaceuticals reported an EPS of -€10.608 in its last earnings report, missing expectations of -€8.518. Following the earnings report the stock price went down -10.974%.
Which hedge fund is a major shareholder of Eiger Biopharmaceuticals?
Among the largest hedge funds holding Eiger Biopharmaceuticals’s share is Carlson Capital LP. It holds Eiger Biopharmaceuticals’s shares valued at N/A.
---
Eiger Biopharmaceuticals Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€27.33 (342.15% Upside)
€27.33 (342.15% Upside)
Insider Transactions
Bought Shares
Worth $77.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.51%
12-Months-Change
Fundamentals
Return on Equity
-225.93%
Trailing 12-Months
Asset Growth
-61.28%
Trailing 12-Months
Company Description
Eiger Biopharmaceuticals
Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of well-characterized drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies. The company was founded by David A. Cory on November 6, 2008 and is headquartered in Palo Alto, CA.
---
72C1 Earnings Call
Q3 2022
0:00 / 0:00
---
72C1 Stock 12 Months Forecast
Average Price Target
€27.33
▲(342.15% Upside)
Technical Analysis
Eiger Biopharmaceuticals
―
BioCryst
―
Sangamo Biosciences
―
RegenXBio
―
Kodiak Sciences
―
Best Analysts Covering 72C1
1 Year
1 Year Success Rate
4/31 ratings generated profit
1 Year Average Return
-34.73%
reiterated a buy rating 6 months ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 12.90% of your transactions generating a profit, with an average return of -34.73% per trade.
---